Thalidomide inhibits TNF response and increases survival following endotoxin injection in rats

被引:31
作者
Schmidt, H
Rush, B
Simonian, G
Murphy, T
Hsieh, J
Condon, M
机构
关键词
D O I
10.1006/jsre.1996.0237
中图分类号
R61 [外科手术学];
学科分类号
摘要
Sepsis is a leading Cause of death following major trauma and complicated abdominal surgery. Tumor necrosis factor-cy (TNF) is believed to be a central mediator in the inflammatory response syndrome. Numerous methods of blunting the TNF response in sepsis have been attempted with suggestion of increased survival and decreased organ injury. Thalidomide, shown in vitro to selectively inhibit TNF production, has been used clinically in states of chronic TNF elevation with encouraging results. In this study, we examined the effect of thalidomide administration in a rat model of acute septic shock. Femoral artery cannulation was performed and baseline TNF measured. Dose response was determined by giving varying doses of thalidomide by gavage. Rats were injected intraarterially with endotoxin and serial samples drawn. TNF was measured by ELISA. For survival, thalidomide was given by gavage and endotoxin injected intraperitoneally. Serum TNF elevation occurred after endotoxin injection with peak levels at 90 min. Thalidomide treated rats had lower TNF levels at all time points (P = <0.01 at 90 and 120 min), with the inhibition being dose dependent. Survival in treated rats exceeded that of untreated rats (53% vs 19%, P = <0.05) at 48 and 72 hr. In conclusion, we found that thalidomide administration leads to increased survival following acute endotoxemia, which may be due to the observed TNF inhibition. (C) 1996 Academic Press, Inc.
引用
收藏
页码:143 / 146
页数:4
相关论文
共 20 条
[1]   DETERMINATION OF THALIDOMIDE IN PLASMA AND BLOOD BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY - AVOIDING HYDROLYTIC DEGRADATION [J].
ERIKSSON, T ;
BJORKMAN, S ;
FYGE, A ;
EKBERG, H .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1992, 582 (1-2) :211-216
[2]  
ERIKSSON T, 1992, TRANSPLANT P, V24, P2560
[3]   A CONTROLLED CLINICAL-TRIAL OF E5 MURINE MONOCLONAL IGM ANTIBODY TO ENDOTOXIN IN THE TREATMENT OF GRAM-NEGATIVE SEPSIS [J].
GREENMAN, RL ;
SCHEIN, RMH ;
MARTIN, MA ;
WENZEL, RP ;
MACINTYRE, NR ;
EMMANUEL, G ;
CHMEL, H ;
KOHLER, RB ;
MCCARTHY, M ;
PLOUFFE, J ;
RUSSELL, JA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 266 (08) :1097-1102
[4]  
Hinshaw LPP, 1987, NEW ENGL J MED, V317, P659
[5]   PENTOXIFYLLINE SUPPRESSES INTERLEUKIN-2-MEDIATED ACTIVATION OF IMMATURE HUMAN NATURAL-KILLER-CELLS BY INHIBITING ENDOGENOUS TUMOR-NECROSIS-FACTOR-ALPHA SECRETION [J].
JEWETT, A ;
BONAVIDA, B .
JOURNAL OF CLINICAL IMMUNOLOGY, 1994, 14 (01) :31-38
[6]   IMPROVEMENTS IN SOLUBILITY AND STABILITY OF THALIDOMIDE UPON COMPLEXATION WITH HYDROXYPROPYL-BETA-CYCLODEXTRIN [J].
KRENN, M ;
GAMCSIK, MP ;
VOGELSANG, GB ;
COLVIN, OM ;
LEONG, KW .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1992, 81 (07) :685-689
[7]   PENTOXIFYLLINE PREVENTS TUMOR NECROSIS FACTOR-INDUCED LUNG INJURY [J].
LILLY, CM ;
SANDHU, JS ;
ISHIZAKA, A ;
HARADA, H ;
YONEMARU, M ;
LARRICK, JW ;
SHI, TX ;
OHANLEY, PT ;
RAFFIN, TA .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1989, 139 (06) :1361-1368
[8]   THALIDOMIDE INHIBITS THE REPLICATION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 [J].
MAKONKAWKEYOON, S ;
LIMSONPOBRE, RNR ;
MOREIRA, AL ;
SCHAUF, V ;
KAPLAN, G .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (13) :5974-5978
[9]  
MELLIN G W, 1962, N Engl J Med, V267, P1184, DOI 10.1056/NEJM196212062672305
[10]   THALIDOMIDE EXERTS ITS INHIBITORY-ACTION ON TUMOR-NECROSIS-FACTOR-ALPHA BY ENHANCING MESSENGER-RNA DEGRADATION [J].
MOREIRA, AL ;
SAMPAIO, EP ;
ZMUIDZINAS, A ;
FRINDT, P ;
SMITH, KA ;
KAPLAN, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 177 (06) :1675-1680